A
ABVC BioPharma, Inc. (ABVC)
NCM – Real Time Price. Currency in USD
1.53
+0.08 (5.52%)
At close: Jun 26, 2026, 4:00 PM EDT
1.57
+0.04 (2.61%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.53
+0.08 (5.52%)
At close: Jun 26, 2026, 4:00 PM EDT
1.57
+0.04 (2.61%)
After-hours: Jun 26, 2026, 7:59 PM EDT
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
| Name | Position |
|---|---|
| Dr. Tsung-Shann Jiang EMBA, Ph.D. | Chief Scientific Officer, Chief Strategy Officer & Director |
| Dr. Uttam Yashwant Patil Ph.D. | CEO & Interim CFO |
| Mr. Eugene Jiang | Chairman & Chief Business Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-18 | 10-Q | ea0290931-10q_abvc.htm |
| 2026-05-15 | NT 10-Q | ea0291128-nt10q_abvcbio.htm |
| 2026-03-27 | POS AM | ea0283341-posam5_abvcbio.htm |
| 2026-03-27 | 8-K | ea028361801-8k_abvcbiopharm.htm |
| 2026-03-05 | DEF 14A | ea0279808-def14a_abvc.htm |
| 2026-03-03 | 8-K | ea0279143-8k_abvc.htm |
| 2026-03-03 | 10-Q/A | ea0278312-10qa1_abvc.htm |
| 2026-03-03 | 10-K | ea0278313-10k_abvcbio.htm |
| 2026-02-05 | PRE 14A | ea0275861-pre14a_abvc.htm |
| 2026-01-16 | 8-K/A | ea0272768-8ka1_abvc.htm |